Provided by Tiger Trade Technology Pte. Ltd.

CLINUVEL PHARMACEUTICALS LTD

8.130
-0.230-2.75%
Volume:129.80K
Turnover:1.06M
Market Cap:408.13M
PE:12.17
High:8.350
Open:8.250
Low:8.030
Close:8.360
52wk High:13.399
52wk Low:7.930
Shares:50.20M
Float Shares:41.32M
Volume Ratio:0.85
T/O Rate:0.31%
Dividend:0.05
Dividend Rate:0.62%
EPS(TTM):0.668
EPS(LYR):0.668
ROE:13.21%
ROA:8.94%
PB:1.50
PE(LYR):12.17

Loading ...

Company Profile

Company Name:
CLINUVEL PHARMACEUTICALS LTD
Exchange:
ASX
Establishment Date:
1999
Employees:
16
Office Location:
535 Bourke Street,Level 22,Melbourne,Victoria,Australia
Zip Code:
3000
Fax:
61 3 9660 4999
Introduction:
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of severe genetic and skin disorders in Europe, the United States, and Singapore. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria. The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with erythropoietic protoporphyria in the People's Republic of China. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.